MRKR News and Press, Marker Therapeutics Inc. From 11/22/22

HOUSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, tod...

Marker Therapeutics press release ( NASDAQ: MRKR ): Q3 GAAP EPS of -$0.08. Revenue of $3.9M. For further details see: Marker Therapeutics GAAP EPS of -$0.08, revenue of $3.9M

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, tod...

Summary AlloVir, Inc. has some solid data in an area of unmet need. AlloVir is well-capitalized to complete its trials. However, the market doesn't seem interested at present. AlloVir , Inc. ( ALVR ) is a leader in the development of allogeneic, virus-specifi...

Cheap Penny Stocks to Buy For Under $1 If you’re watching the action in the stock market today, you’re seeing plenty of chop. The U.S. dollar’s strength has pushed broader markets lower, but a mix of positive and negative economic against this week’s PPI data...

Marker Therapeutics, Inc. ( NASDAQ: MRKR ), a biotech focused on T cell-based immunotherapies, announced Tuesday that the FDA awarded a $2M grant to support its Phase 2 ARTEMIS trial for liquid tumor candidate MT-401 in patients with post-transplant acute myeloid leukemia (AML...

HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today an...

HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, to...

Marker Therapeutics press release ( NASDAQ: MRKR ): Q2 GAAP EPS of -$0.11 misses by $0.01 . Revenue of $0.79M misses by $1.71M . “We are very optimistic about the ability of MT-401 to drive results for patients with measurable residual disease given the ...

HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, tod...